

2.15.01

FEB 15 2001

02-26-2001



101620878

RECORDATION FORM COVER SHEET  
TRADEMARKS ONLY

TO: The Commissioner of Patents and Trademarks: Please record the attached original document(s) or copy(ies).

Submission Type

- New
- Resubmission (Non-Recordation)  
Document ID # \_\_\_\_\_
- Correction of PTO Error  
Reel # \_\_\_\_\_ Frame # \_\_\_\_\_
- Corrective Document  
Reel # \_\_\_\_\_ Frame # \_\_\_\_\_

Conveyance Type

- Assignment  License
- Security Agreement  Nunc Pro Tunc Assignment  
Effective Date  
Month Day Year  
12151999
- Merger
- Change of Name
- Other \_\_\_\_\_

Conveying Party

Mark if additional names of conveying parties attached

Execution Date  
Month Day Year

Name Rhone-Poulenc Rorer Pharmaceuticals Inc. 1215199

Formerly \_\_\_\_\_

- Individual  General Partnership  Limited Partnership  Corporation  Association
- Other \_\_\_\_\_
- Citizenship/State of Incorporation/Organization Delaware

Receiving Party

Mark if additional names of receiving parties attached

Name Aventis Pharmaceuticals Products Inc.

DBA/AKA/TA \_\_\_\_\_

Composed of \_\_\_\_\_

Address (line 1) Route 202-206

Address (line 2) \_\_\_\_\_

Address (line 3) Bridgewater NJ 08807-0800  
City State/Country Zip Code

- Individual  General Partnership  Limited Partnership  If document to be recorded is an assignment and the receiving party is not domiciled in the United States, an appointment of a domestic representative should be attached. (Designation must be a separate document from Assignment.)
- Corporation  Association
- Other \_\_\_\_\_
- Citizenship/State of Incorporation/Organization Delaware

FOR OFFICE USE ONLY

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document and gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project (0651-0027), Washington, D.C. 20503. See OMB Information Collection Budget Package 0651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS.

Mail documents to be recorded with required cover sheet(s) information to:  
Commissioner of Patents and Trademarks, Box Assignments, Washington, D.C. 20231

TRADEMARK  
REEL: 002240 FRAME: 0482

**Domestic Representative Name and Address**

Enter for the first Receiving Party only.

Name

Address (line 1)

Address (line 2)

Address (line 3)

Address (line 4)

FEB 15 2001

**Correspondent Name and Address**

Area Code and Telephone Number

215-923-4466

Name  Synnestvedt & Lechner LLP

Address (line 1)  2600 Aramark Tower

Address (line 2)  1101 Market Street

Address (line 3)  Philadelphia, PA 19107-2950

Address (line 4)

**Pages**

Enter the total number of pages of the attached conveyance document including any attachments.

#

2

**Trademark Application Number(s) or Registration Number(s)**

Mark if additional numbers attached

Enter either the Trademark Application Number or the Registration Number (DO NOT ENTER BOTH numbers for the same property).

**Trademark Application Number(s)**

**Registration Number(s)**

<input type="text"/>	<input type="text"/>	<input type="text"/>	1369780	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>
<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>

**Number of Properties**

Enter the total number of properties involved.

#

1

**Fee Amount**

Fee Amount for Properties Listed (37 CFR 3.41):

\$

40.00

Method of Payment:

Enclosed

Deposit Account

Deposit Account

(Enter for payment by deposit account or if additional fees can be charged to the account.)

Deposit Account Number:

#

19-5425

Authorization to charge additional fees:

Yes

No

**Statement and Signature**

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document. Charges to deposit account are authorized, as indicated herein.

Bryna S. Silver, A Member of the PA Bar

*Bryna S. Silver*

February 13, 2001


Name of Person Signing

Signature

Date Signed

Office of the Secretary of State

I, EDWARD J. FREEL, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF AMENDMENT OF "RHONE-POULENC RORER PHARMACEUTICALS INC.", CHANGING ITS NAME FROM "RHONE-POULENC RORER PHARMACEUTICALS INC." TO "AVENTIS PHARMACEUTICALS PRODUCTS INC.", FILED IN THIS OFFICE ON THE FIFTEENTH DAY OF DECEMBER, A.D. 1999, AT 11:30 O'CLOCK A.M.



*Edward J. Freel*

Edward J. Freel, Secretary of State

0631221 8100

991542800

AUTHENTICATION:

DATE:

0145881

12-16-99

CERTIFICATE OF AMENDMENT  
OF  
CERTIFICATE OF INCORPORATION  
OF  
RHONE-POULENC RORER PHARMACEUTICALS INC.

The undersigned, being officers of Rhône-Poulenc Rorer Pharmaceuticals Inc. (the "Company"), for the purpose of amending the Certificate of Incorporation pursuant to the provisions of Sections 228 and 242 of the Delaware General Corporation Law, hereby execute the following Certificate of Amendment:

FIRST: The name of the corporation is RHONE-POULENC RORER PHARMACEUTICALS INC.

SECOND: The following amendment was adopted by the directors and sole shareholder in the manner prescribed by the Delaware General Corporation Law:

Article FIRST of the Certificate of Incorporation is hereby amended to read as follows:

"The name of the corporation is Aventis Pharmaceuticals Products Inc."

IN WITNESS WHEREOF, the undersigned have caused this Certificate of Amendment of the Certificate of Incorporation to be duly executed by its Senior Vice President and attested by its Assistant Secretary this 15th day of December, 1999.

RHONE-POULENC RORER PHARMACEUTICALS INC.

By:

  
John R. Leone

Senior Vice President & General Manger